These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29071405)

  • 1. Requirements for Using iPSC-Based Cell Models for Assay Development in Drug Discovery.
    Christensen K; Roudnicky F; Patsch C; Burcin M
    Adv Biochem Eng Biotechnol; 2018; 163():207-220. PubMed ID: 29071405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.
    Haggarty SJ; Silva MC; Cross A; Brandon NJ; Perlis RH
    Mol Cell Neurosci; 2016 Jun; 73():104-15. PubMed ID: 26826498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances in Disease Modeling and Drug Discovery for Diabetes Mellitus Using Induced Pluripotent Stem Cells.
    Kawser Hossain M; Abdal Dayem A; Han J; Kumar Saha S; Yang GM; Choi HY; Cho SG
    Int J Mol Sci; 2016 Feb; 17(2):256. PubMed ID: 26907255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New lessons learned from disease modeling with induced pluripotent stem cells.
    Onder TT; Daley GQ
    Curr Opin Genet Dev; 2012 Oct; 22(5):500-8. PubMed ID: 22749051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iPSC technology: platform for drug discovery. Point.
    Ellis J; Bhatia M
    Clin Pharmacol Ther; 2011 May; 89(5):639-41. PubMed ID: 21512521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new era of disease modeling and drug discovery using induced pluripotent stem cells.
    Suh W
    Arch Pharm Res; 2017 Jan; 40(1):1-12. PubMed ID: 27921262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concise Review: Induced Pluripotent Stem Cell-Based Drug Discovery for Mitochondrial Disease.
    Inak G; Lorenz C; Lisowski P; Zink A; Mlody B; Prigione A
    Stem Cells; 2017 Jul; 35(7):1655-1662. PubMed ID: 28544378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced pluripotent stem cells--opportunities for disease modelling and drug discovery.
    Grskovic M; Javaherian A; Strulovici B; Daley GQ
    Nat Rev Drug Discov; 2011 Nov; 10(12):915-29. PubMed ID: 22076509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of induced pluripotent stem cells in drug development.
    Inoue H; Yamanaka S
    Clin Pharmacol Ther; 2011 May; 89(5):655-61. PubMed ID: 21430656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening.
    Chang CY; Ting HC; Liu CA; Su HL; Chiou TW; Lin SZ; Harn HJ; Ho TJ
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32344649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases.
    Hung SSC; Khan S; Lo CY; Hewitt AW; Wong RCB
    Pharmacol Ther; 2017 Sep; 177():32-43. PubMed ID: 28223228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-Based Assays Using Differentiated Human Induced Pluripotent Cells.
    Cader Z; Graf M; Burcin M; Mandenius CF; Ross JA
    Methods Mol Biol; 2019; 1994():1-14. PubMed ID: 31124100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery.
    Corti S; Faravelli I; Cardano M; Conti L
    Expert Opin Drug Discov; 2015 Jun; 10(6):615-29. PubMed ID: 25891144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery.
    Liu JT; Lamprecht MP; Duncan SA
    J Vis Exp; 2018 May; (135):. PubMed ID: 29863663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells.
    Giri S; Bader A
    Drug Discov Today; 2015 Jan; 20(1):37-49. PubMed ID: 25448756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulosa cell-derived induced pluripotent stem cells exhibit pro-trophoblastic differentiation potential.
    Chuang CY; Huang MC; Chen HF; Tseng LH; Yu CY; Stone L; Huang HP; Ho HN; Kuo HC
    Stem Cell Res Ther; 2015 Feb; 6(1):14. PubMed ID: 25889179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA-Generated and Gene-Edited Induced Pluripotent Stem Cells for Disease Modeling and Therapy.
    Kehler J; Greco M; Martino V; Pachiappan M; Yokoe H; Chen A; Yang M; Auerbach J; Jessee J; Gotte M; Milanesi L; Albertini A; Bellipanni G; Zucchi I; Reinbold RA; Giordano A
    J Cell Physiol; 2017 Jun; 232(6):1262-1269. PubMed ID: 27631155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. iPS cell derived neuronal cells for drug discovery.
    Heilker R; Traub S; Reinhardt P; Schöler HR; Sterneckert J
    Trends Pharmacol Sci; 2014 Oct; 35(10):510-9. PubMed ID: 25096281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery.
    Zhang R; Zhang LH; Xie X
    Acta Pharmacol Sin; 2013 Jun; 34(6):765-76. PubMed ID: 23603980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.